Article: The Importance of a Robust Formulation
The Importance of a Robust Formulation for Long-Term Drug Development Success
This new article from Coriolis Pharma emphasizes the importance of robust formulations for biologic drug success. It showcases Coriolis’ integrated, science-driven approach using in-silico tools and high-throughput methods to create stable, future-ready formulations from early development onward.
Robust formulations are the backbone of successful biologic drug products — ensuring safety, efficacy, and stability throughout the product life cycle. Achieving this requires a unified strategy that integrates deep scientific knowledge, early-stage modeling, platform-based assessments (where appropriate), and process-aware development. With advanced in-silico tools, high-throughput screening platforms, and a collaborative, science-first approach, Coriolis Pharma helps drug developers design formulations that are not only resilient, but ready for the future.
Robust formulations are defined by their ability to remain stable, safe, and effective throughout their intended shelf lives — typically 24 to 36 months at refrigerated conditions for biologics. Achieving this robustness is essential for long-term drug product success and requires a combination of both formulation and manufacturing robustness.
Manufacturing robustness, meanwhile, ensures that the drug product can be produced consistently at the desired quality level even when small fluctuations in critical process conditions occur. This aspect is evaluated and refined continuously throughout the development process, particularly during scale-up and technical transfer stages. It is closely linked to process understanding, as even minor deviations in filtration pressures, mixing rates, or temperatures can have significant impacts on product integrity and stability.
Together, formulation and manufacturing robustness underpin the reliability and performance of a drug product over time and across production scales. Because these attributes influence every stage of development — from preclinical formulation through commercial manufacturing — it is critical to approach robustness in a phase-appropriate way as a long-term strategy rather than a late-stage correction.
